Latest News

Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.

In a single day, the FDA cleared the first nonprescription apraclonidine drop, the first at-home subcutaneous therapy for thyroid eye disease, and a presbyopia indication for an established pupil-modulating drop.

An association has been identified between primary open-angle glaucoma and erectile dysfunction.

Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation choice.

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

Himani Goyal, MD, reviews a patient case and discusses what a multispecialty group is seeing in practice.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, and the future of reimbursement.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.

Enrollment in the licaminlimab trial closed above target, with two-thirds of 176 patients carrying a TNFR1 variant associated with stronger treatment response. Topline data are expected around year-end 2026.

Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.

Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.

The nonprescription 0.125% apraclonidine drop is approved for adults and children 12 years and older, and Alcon says each dose whitens the eye for up to 12 hours.